Publication: Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life
Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life
Date
Date
Date
Citations
Richter, C., Hafner, J., Schuermann, M., Tanadini, M., Trisconi, N., Schmid-Grendelmeier, P., Kündig, T., Nägeli, M., Brüggen, M.-C., & Guillet, C. (2023). Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life. Dermatology, 239(5), 811–817. https://doi.org/10.1159/000531708
Abstract
Abstract
Abstract
Background: Chronic prurigo (CPG) is a pruritic skin disease, characterized by an itch-scratch cycle and scarring. It reduces patients’ quality of life (QoL). Dupilumab is a monoclonal human IgG antibody that inhibits signaling of the interleukin 4 (IL-4) and interleukin 13 (IL-13) pathways through blockade of the IL-4 receptor. Patients with CPG who receive dupilumab often report great improvement in itch and overall QoL. We therefore reviewed our experience in order to follow up on QoL, safety, and treatment response in patients wit
Metrics
Downloads
Views
Citations
Additional indexing
Creators (Authors)
- Richter, Clara
- Hafner, Jürg
- Schuermann, Manuel
- Tanadini, Matteo
- Trisconi, Nisia
- Schmid-Grendelmeier, Peter
- Kündig, Thomas
- Nägeli, Mirjam
- Brüggen, Marie-Charlotte
- Guillet, Carole
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Metrics
Downloads
Views
Citations
Citations
Richter, C., Hafner, J., Schuermann, M., Tanadini, M., Trisconi, N., Schmid-Grendelmeier, P., Kündig, T., Nägeli, M., Brüggen, M.-C., & Guillet, C. (2023). Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life. Dermatology, 239(5), 811–817. https://doi.org/10.1159/000531708
